3 Biotech Stocks That Could Rocket Higher
Over the past year, these small-cap drugmakers have done well by their shareholders, and more big catalysts could be coming.
Over the past year, these small-cap drugmakers have done well by their shareholders, and more big catalysts could be coming.
These companies pay hefty dividends and have big capital appreciation potential.
Which of these two high-growth chipmakers deserves your money?
Jazz Pharma is not the most popular drugmaker, but it is definitely worth a second look.
Yes, but it often doesn’t have much to do with revenue.
These fundamentally strong stocks are about to get even more attractive in the second half of 2021.
The stock of Zomato settled at Rs 125.85, up 65.59 percent, against its issue price of Rs 76 on Friday. Let#39;s look at some…
Teladoc Health was the first mover, but it’s no longer top dog by some standards.
The future is renewables, but fossil fuels remain the dominant source of energy. Should dividend investors focus on the future,…
Read as much as possible about the company#39;s business and operations before investing in an IPO.